RMC4630

RMC4630 · Revolution Medicines, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for RMC4630, covering 2023-06-26 to 2023-06-26. Get the full timeline:

Most recent: Clinical Trial Update: Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC [Phase 1, Phase 2]

See pricing